GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Bioequivalence Study of SB797620 in Healthy Japanese Volunteers

Phase 1

Withdrawn

Conditions: Healthy Subjects

First Posted Date: 2007-10-25

Last Posted Date: 2015-02-23

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT00549263

KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects

Phase 4

Completed

Conditions: Infection, Human Immunodeficiency Virus I
HIV Infection

Interventions: Drug: Abacavir/lamivudine and efavirenz
Drug: Tenofovir/Emtricitabine and efavirenz

First Posted Date: 2007-10-25

Last Posted Date: 2011-04-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 392

Registration Number: NCT00549198

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius

Phase 2

Terminated

Conditions: Fracture Healing

Interventions: Drug: SB-751689
Other: Placebo

First Posted Date: 2007-10-24

Last Posted Date: 2017-04-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 86

Registration Number: NCT00548496

Locations: 🇬🇧
GSK Investigational Site, Edinburgh, Midlothian, United Kingdom

Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Formulation A
Drug: Formulation B
Drug: Formulation C
Drug: Formulation D

First Posted Date: 2007-10-24

Last Posted Date: 2017-08-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 37

Registration Number: NCT00548769

Locations: 🇵🇱
GSK Investigational Site, Poznan, Poland

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058

Phase 4

Completed

Conditions: Diphtheria
Acellular Pertussis
Tetanus
Diphtheria-Tetanus-acellular Pertussis Vaccines

Interventions: Biological: Boostrix™

First Posted Date: 2007-10-23

Last Posted Date: 2020-01-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 203

Registration Number: NCT00548171

Locations: 🇦🇺
GSK Investigational Site, Westmead, New South Wales, Australia

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

Phase 3

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Synflorix
Biological: Tritanrix-HepB
Biological: Hiberix
Biological: Poliorix
Biological: Prevenar (Wyeth)
Biological: Polio Sabin

First Posted Date: 2007-10-22

Last Posted Date: 2019-01-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 756

Registration Number: NCT00547248

Locations: 🇵🇱
GSK Investigational Site, Wroclaw, Poland

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

Phase 2

Completed

Conditions: Infections, Papillomavirus

Interventions: Biological: Cervarix™

First Posted Date: 2007-10-18

Last Posted Date: 2018-06-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 116

Registration Number: NCT00546078

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

Revaccination With Influenza Vaccine GSK1247446A

Phase 2

Completed

Conditions: Influenza, Human
Influenza

Interventions: Biological: Influenza Vaccine GSK1247446A
Biological: Fluarix™

First Posted Date: 2007-10-16

Last Posted Date: 2019-06-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 243

Registration Number: NCT00545025

Locations: 🇧🇪
GSK Investigational Site, Wilrijk, Belgium

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

Phase 4

Terminated

Conditions: Acellular Pertussis
Diphtheria
Tetanus

First Posted Date: 2007-10-16

Last Posted Date: 2016-09-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 720

Registration Number: NCT00544271

Locations: 🇦🇺
GSK Investigational Site, Carlton, Victoria, Australia

Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)

Phase 2

Withdrawn

Conditions: Venous Thromboembolism

First Posted Date: 2007-10-10

Last Posted Date: 2013-04-04

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT00541320

Locations: 🇺🇸
GSK Clinical Trials Call Center', Phoenix, Arizona, United States
🇺🇸
GSK Clinical Trials Call Center, San Antonio, Texas, United States

Home Terms & Conditions Privacy Policy